Treatment plan prescreening for patient-specific quality assurance measurements using independent Monte Carlo dose calculations.

Yuan Xu,Ke Zhang,Zhiqiang Liu,Bin Liang,Xiangyu Ma,Wenting Ren,Kuo Men,Jianrong Dai

Frontiers in oncology（2022）

引用 2|浏览14

暂无评分

摘要

Independent dose calculation with the MC-based program ArcherQA has potential as a prescreen treatment for measurement-based patient-specific QA. AUC values (>0.9) showed excellent classification accuracy for monitoring failing plans with independent MC calculations.

查看译文

关键词

ArcherQA,Monte Carlo,dosimetric verification,independent dose verification,patient-specific QA

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要